Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Green Tea Catechins Against COVID-19: Lower COVID-19 Morbidity and Mortality in Countries with Higher per capita Green Tea Consumption

Author(s): Maksim Storozhuk*

Volume 3, Issue 3, 2022

Published on: 15 March, 2022

Article ID: e240122200469 Pages: 8

DOI: 10.2174/2666796703666220124103039

Abstract

Background: Several vaccines are currently validated for COVID-19 prevention and mass vaccination has already been started in many countries. Nevertheless, it is likely that the development of an efficient therapy that reduces COVID-19 severity/mortality would be still important for a rather prolonged time, in particular, due to new variants of SARS-CoV-2. Several lines of emerging evidence suggest that green tea catechins such as epigallocatechin-3-gallate have direct anti-viral activity and affect factors associated with COVID-19 severity.

Objective: Considering that green tea catechins are major constituents of green tea, it may be expected that countries with higher per capita green tea consumption would be less affected by COVID-19. This study assessed this possibility.

Methods: Among countries with a population of at least 3 million (n=134), those with relatively high (above 150 g) per capita green tea consumption have been identified (n=21); (ii) normalized to population values of COVID-19 cases (morbidity) and deaths (mortality) for groups of countries with high and low per capita green tea consumption were compared.

Results: Striking differences in COVID-19 morbidity and mortality between groups of countries with ‘high’ and ‘low’ green tea consumption were found. The differences were still observed after the adjustment for the onset of the disease. An analysis using the multiple linear regression approach suggests that the associations are present at the level of individual countries.

Conclusion: Results of this study, taken together with emerging pharmacological evidence, suggest that green tea catechins can give valuable clues for the treatment/amelioration of COVID-19.

Keywords: Catechins, SARS-CoV-2, (-)-epigallocatechin (EGC), (-)-epigallocatechin-3-gallate (EGCG), anti-viral activity, green tea.

Graphical Abstract

[1]
Xu J, Xu Z, Zheng W. A review of the antiviral role of green tea catechins. Molecules 2017; 22(8): 1337.
[http://dx.doi.org/10.3390/molecules22081337] [PMID: 28805687]
[2]
Mhatre S, Srivastava T, Naik S, Patravale V. Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review. Phytomedicine 2020; 153286
[http://dx.doi.org/10.1016/j.phymed.2020.153286] [PMID: 32741697]
[3]
Furushima D, Ide K, Yamada H. Effect of tea catechins on influenza infection and the common cold with a focus on epidemiological/clinical studies. Molecules 2018; 23(7): E1795.
[http://dx.doi.org/10.3390/molecules23071795] [PMID: 30037024]
[4]
Nanri A, Nakamoto K, Sakamoto N, Imai T, Mizoue T. Green tea consumption and influenza infection among Japanese employees. Eur J Clin Nutr 2021; 75(6): 976-9.
[http://dx.doi.org/10.1038/s41430-020-00792-3] [PMID: 33139853]
[5]
Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020; 10(5): 766-88.
[http://dx.doi.org/10.1016/j.apsb.2020.02.008] [PMID: 32292689]
[6]
Jang M, Park YI, Cha YE, et al. Tea polyphenols EGCG and theaflavin inhibit the activity of sars-cov-2 3cl-protease in vitro. Evid Based Complement Alternat Med 2020; 2020: 5630838.
[http://dx.doi.org/10.1155/2020/5630838] [PMID: 32963564]
[7]
Jang M, Park R, Park YI, et al. EGCG, a green tea polyphenol, inhibits human coronavirus replication in vitro. Biochem Biophys Res Commun 2021; 547: 23-8.
[http://dx.doi.org/10.1016/j.bbrc.2021.02.016] [PMID: 33588235]
[8]
Park J, Park R, Jang M, Park YI. Therapeutic potential of EGCG, a green tea polyphenol, for treatment of coronavirus diseases. Life (Basel) 2021; 11(3): 197.
[http://dx.doi.org/10.3390/life11030197] [PMID: 33806274]
[9]
Liu J, Bodnar BH, Meng F, et al. Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor. Cell Biosci 2021; 11(1): 168.
[http://dx.doi.org/10.1186/s13578-021-00680-8] [PMID: 34461999]
[10]
Momose Y, Maeda-Yamamoto M, Nabetani H. Systematic review of green tea epigallocatechin gallate in reducing low-density lipoprotein cholesterol levels of humans. Int J Food Sci Nutr 2016; 67(6): 606-13.
[http://dx.doi.org/10.1080/09637486.2016.1196655] [PMID: 27324590]
[11]
Khan N, Mukhtar H. Tea and health: Studies in humans. Curr Pharm Des 2013; 19(34): 6141-7.
[http://dx.doi.org/10.2174/1381612811319340008] [PMID: 23448443]
[12]
Lin Y, Shi D, Su B, et al. The effect of green tea supplementation on obesity: A systematic review and dose-response meta-analysis of randomized controlled trials. Phytother Res 2020; 34(10): 2459-70.
[http://dx.doi.org/10.1002/ptr.6697] [PMID: 32372444]
[13]
Abe SK, Inoue M. Green tea and cancer and cardiometabolic diseases: A review of the current epidemiological evidence. Eur J Clin Nutr 2021; 75(6): 865-76.
[http://dx.doi.org/10.1038/s41430-020-00710-7] [PMID: 32820240]
[14]
Menegazzi M, Campagnari R, Bertoldi M, Crupi R, Di Paola R, Cuzzocrea S. Protective effect of epigallocatechin-3-gallate (EGCG) in diseases with uncontrolled immune activation: Could such a scenario be helpful to counteract COVID-19? Int J Mol Sci 2020; 21(14): 5171.
[http://dx.doi.org/10.3390/ijms21145171] [PMID: 32708322]
[15]
Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: The current evidence and treatment strategies. Front Immunol 2020; 11: 1708.
[http://dx.doi.org/10.3389/fimmu.2020.01708] [PMID: 32754163]
[16]
Wessels I, Rolles B, Rink L. The potential impact of zinc supplementation on COVID-19 pathogenesis. Front Immunol 2020; 11: 1712.
[http://dx.doi.org/10.3389/fimmu.2020.01712] [PMID: 32754164]
[17]
IARC. Coffee, tea, mate, methylxanthines and methylglyoxal. IARC working group on the evaluation of carcinogenic risks to humans. Lyon, 27 February to 6 March 1990. IARC Monogr Eval Carcinog Risks Hum 1991; 51: 1-513.
[PMID: 1674554]
[18]
Kosugi Yukio. Green tea consumption. World Green Tea Association 2020. Available from: http://www o-cha net/english/teacha/distribution/greentea3 html (Accessed on June 12, 2021).
[19]
Tea research and extension station. Taiwan tea industry 2020. Available from: https://www tres gov tw/en/ws php?id=1000 (Accessed on June 12, 2021).
[20]
Intergovernmental Group on Tea, Food and Agriculture Organization (FAO) of the United Nations (2018) a. Current market situation and medium term outlook. 2018. Available from: http://www fao org/economic/est/est-commodities/tea/tea-meetings/tea23/en/
[21]
Intergovernmental Group on Tea, Food and Agriculture Organization (FAO) of the United Nations) (2018)b. Emerging trends in tea consumption: Informing a generic promotion process 2018. Available from: http://www fao org/economic/est/est-commodities/tea/tea-meetings/tea23/en/ (Accessed on June 12, 2021).
[22]
United Nations Statistics Division. Commodity trade statistics database. Available from: http://data.un.org/Data.aspx?d=Com Trade&f=_l1Code%3A10 (Accessed on June 12, 2021).
[23]
Worldometers info. Coronavirus update 2020. Available from: https://www worldometers info/coronavirus/ (Accessed on June 12, 2021).
[24]
Urashima M, Otani K, Hasegawa Y, Akutsu T. BCG vaccination and mortality of COVID-19 across 173 countries: An ecological study. Int J Environ Res Public Health 2020; 17(15): 5589.
[http://dx.doi.org/10.3390/ijerph17155589] [PMID: 32756371]
[25]
Klinger D, Blass I, Rappoport N, Linial M. Significantly improved COVID-19 outcomes in countries with higher BCG vaccination coverage: A multivariable analysis. Vaccines (Basel) 2020; 8(3): 378.
[http://dx.doi.org/10.3390/vaccines8030378] [PMID: 32664505]
[26]
World Bank. Population density (people per sq. km of land area). 2019. Available from: https://data worldbank org/indicator/EN POP DNST
[27]
worldbank.org. Population ages 65 and above (% of total population). 2019. Available from: https://data worldbank org/indicator/SP POP 65UP TO ZS
[28]
World Bank. Urban population (% of total population). 2019. Available from: https://data worldbank org/indicator/SP URB TOTL IN ZS
[29]
UN. United Nations development program. Human development Reports (2019). Available from: http://hdr undp org/en/content/2019-human-development-index-ranking (Accessed on June 12, 2021).
[30]
Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci USA 2020; 117(30): 17720-6.
[http://dx.doi.org/10.1073/pnas.2008410117] [PMID: 32647056]
[31]
Tukey J. Exploratory data analysis. Reading, Mass: Addison-Wesley Pub. Co. 1977.
[32]
Hellwig MD, Maia A. A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. Int J Antimicrob Agents 2021; 57(1): 106248.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.106248] [PMID: 33259913]
[33]
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178: 104787.
[http://dx.doi.org/10.1016/j.antiviral.2020.104787] [PMID: 32251768]
[34]
Sharun K, Dhama K, Patel SK, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob 2020; 19(1): 23.
[http://dx.doi.org/10.1186/s12941-020-00368-w] [PMID: 32473642]
[35]
World Health Organization. (WHO) PCT Databank. Available from: WHO. https://www who int/neglected _ diseases/preventive _ chemotherapy/lf/en
[36]
Aguiar M, Stollenwerk N. Condition-specific mortality risk can explain differences in COVID-19 case fatality ratios around the globe. Public Health 2020; 188: 18-20.
[http://dx.doi.org/10.1016/j.puhe.2020.08.021] [PMID: 33049491]
[37]
Madan M, Pahuja S, Mohan A, et al. TB infection and BCG vaccination: Are we protected from COVID-19? Public Health 2020; 185: 91-2.
[http://dx.doi.org/10.1016/j.puhe.2020.05.042] [PMID: 32590235]
[38]
Annweiler C, Hanotte B, Grandin de l’Eprevier C, Sabatier JM, Lafaie L, Célarier T. Vitamin D and survival in COVID-19 patients: A quasi-experimental study. J Steroid Biochem Mol Biol 2020; 204: 105771.
[http://dx.doi.org/10.1016/j.jsbmb.2020.105771] [PMID: 33065275]
[39]
Hajian Tilaki K. Methodological issues of confounding in analytical epidemiologic studies. Caspian J Intern Med 2012; 3(3): 488-95.
[PMID: 24009920]
[40]
Nasrolahi A, Haghani K, Gheysarzadeh A, Bakhtiyari S. Do Genetic factors predispose people to COVID-19: A review article. Curr Mol Med 2021; 21(6): 457-61.
[http://dx.doi.org/10.2174/1566524020999201113102145] [PMID: 33191884]
[41]
Yildirim Z, Sahin OS, Yazar S, Bozok Cetintas V. Genetic and epigenetic factors associated with increased severity of Covid-19. Cell Biol Int 2021; 45(6): 1158-74.
[http://dx.doi.org/10.1002/cbin.11572] [PMID: 33590936]
[42]
Bentlage E, Ammar A, How D, et al. Practical recommendations for maintaining active lifestyle during the COVID-19 pandemic: A systematic literature review. Int J Environ Res Public Health 2020; 17(17): 6265.
[http://dx.doi.org/10.3390/ijerph17176265] [PMID: 32872154]
[43]
Furushima D, Nishimura T, Takuma N, et al. Prevention of acute upper respiratory infections by consumption of catechins in healthcare workers: A randomized, placebo-controlled trial. Nutrients 2019; 12(1): 4.
[http://dx.doi.org/10.3390/nu12010004] [PMID: 31861349]
[44]
Du A, Zheng R, Disoma C, et al. Epigallocatechin-3-gallate, an active ingredient of traditional Chinese medicines, inhibits the 3CLpro activity of SARS-CoV-2. Int J Biol Macromol 2021; 176: 1-12.
[http://dx.doi.org/10.1016/j.ijbiomac.2021.02.012] [PMID: 33548314]
[45]
Chiou WC, Chen JC, Chen YT, et al. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease. Biochem Biophys Res Commun 2021; S0006-291X(20)32299-3 Online ahead of print.
[http://dx.doi.org/10.1016/j.bbrc.2020.12.106] [PMID: 33454058]

Rights & Permissions Print Cite
Article Metrics
20
1
© 2024 Bentham Science Publishers | Privacy Policy